

# Mining microarray data to predict the histological grade of a Breast Cancer

Mickael Fabregue<sup>a</sup>, Sandra Bringay<sup>a,b</sup>, Pascal Poncelet<sup>a</sup>, Maguelonne Teisseire<sup>c</sup>, Béatrice Orsetti<sup>d</sup>

<sup>a</sup>*LIRMM UM2 CNRS, Montpellier, France*

<sup>b</sup>*MIAp UM3, Montpellier, France*

<sup>c</sup>*CEMAGREF, Montpellier, France*

<sup>d</sup>*INSERM U896-UM1-CRLC, Montpellier, France*

*E-mail: bringay@lirmm.fr - Tel: +33 467 418 636 - Fax +33 467 418 585*

## Abstract

**Background:** The aim of this study was to develop an original method to extract sets of relevant molecular biomarkers (gene sequences) that can be used for class prediction and can be included as prognostic and predictive tools. **Materials and Methods:** The method is based on sequential patterns used as features for class prediction. We applied it to classify breast cancer tumors according to their histological grade. **Results:** We obtained very good recall and precision for grade 1 and 3 tumors, but, like other authors, our results were less satisfactory for grade 2 tumors. **Conclusions:** We demonstrated the interest of sequential patterns for class prediction of microarrays and we now have the material to use them for prognostic and predictive applications.

*Keywords:*

Sequential patterns, Microarrays analysis, Breast cancer, Translational Bioinformatics.

---

## 1. Introduction

Breast cancer is a major public health issue today. According to the [breastcancer.org](http://breastcancer.org)<sup>1</sup>, with 192,370 new cases in 2009 in the U.S., breast cancer is the most frequently diagnosed malignancy and the main cause of cancer death in women. One out of eight women will develop breast cancer during her lifetime. New treatments are continually being developed to target specific types of cancer and to reduce potentially adverse effects (cardiac dysfunction, premature menopause, etc.). However, despite early detection and new treatments, up to 50% of the women will develop distant metastases, which are unfortunately incurable today. The three major challenges associated with breast cancer are: (1) How to *diagnose breast cancer* as early as possible through population screening and to identify the type of tumor detected? (2) How to *predict the response* of a patient to a given treatment according to classes of individuals? (3) How to *choose the best therapy* for a given subject with an accurate prognosis including her chances of remission, by deducing from the usual course of the disease its future development and its outcome?

DNA microarrays are powerful tools to draw a genetic portrait of a biological sample (*e.g.*, a tumor sample) by comparing gene expression in different tissues, cells, and conditions, and providing information on the relative levels of expression of thousands of genes among samples. These technologies carry with them the hope of bringing new insights to cancer biology and improving current tools for cancer management. Simon and Dobbin [1] describe three ways of using DNA microarrays:

- *Class comparison* consists in identifying variations (*e.g.*, in the expression of the genes) among  $n$  classes. It can be used to compare normal tissues and tumors [2], and tumors that respond to therapy and those that do not [3], or to distinguish various subtypes of a tumor [4, 5].

Class comparison enables identification of the critical role of certain genes by establishing the

---

<sup>1</sup><http://www.breastcancer.org/>

molecular identity of a class, like a bar code. This code can then be used for class prediction.

- *Class discovery* consists in discovering new subgroups in a population (*e.g.*, subtypes of a tumor) based on the molecular profile. For example, Sotiriou et al. [5] describe subtypes of breast cancer.
- *Class prediction* uses the results of the previous process to assign a new specimen (a new microarray) to a known class, *e.g.* to a subtype of a tumor [6]. If the classifier is confident, the result can be used by medical experts to make clinical decisions (*e.g.*, for population screening) to predict the effects of a treatment for a patient or for prognoses.

The objective of this study was to develop an original method to extract sets of relevant molecular biomarkers (gene sequences) that can be used for class prediction and as a prognostic and predictive tool. Molecular biomarkers are generated from analyses of DNA microarrays and are based on a particular data mining technique: *Sequential pattern discovery*. In [7], we described an efficient algorithm to extract these frequent patterns of correlated genes ordered according to their level of expression. An example of such a pattern is  $\langle (17aag_{o}vca_{dn})(tgz_{a}dip_{up}, rett_{dn}) \rangle, 80\%Gr1, 40\%Gr2$  meaning that "For 80% of Grade 1 tumors, and 40% of Grade 2 tumors, the level of expression of gene *17aag<sub>o</sub>vca<sub>dn</sub>* is lower than that of *tgz<sub>a</sub>dip<sub>up</sub>* and *rett<sub>dn</sub>*, whose levels of expression are very close". Sequential patterns have already been used successfully for text categorization. In this paper, we investigate the relevance of such patterns for tumor classification. The complexity of the data and the interdisciplinary context make this task extremely challenging.

Our contribution is described in terms of methodology, biological findings and medical implications. After briefly presenting the state of the art (section 2), we describe the complete methodology in detail in the material and methods (section 3). We apply this methodology to the study of breast cancer (section 4). To conclude, we discuss how this methodology can be generalized (section 5) according to the kind of data and the data mining approach.

## 2. Background

Due to the amount of data available, processing DNA microarrays in a way that makes biomedical sense is still a major issue. Statistical methods and data mining techniques play a key role in discovering previously unknown knowledge. However, their implementation in this context is difficult because the number of measurement points (gene expression levels) is much higher than the number of samples, which results in the well-known problem of the *curse of dimensionality*, also called the *high feature-to-sample ratio* [4]. Moreover, the correlation structure of the expressions is unknown (gene co-expressions) and the presence of noise is a serious problem. For all these reasons, classification based on microarray data is quite different from previous classifications and traditional methods are not successful [8].

Most studies are based on the search for differentially expressed genes, particularly disease-specific genes. These methods work like a filter and reduce the size of the group of genes in the experiment to a smaller one, which can be more easily investigated. Most widely used methods use univariate procedures often combined with adjustment of P-values or a similar concept [9, 10]. SAM [10] or CyberT [11] are well-known programs based on such techniques. Unlike multivariate approaches such as ANOVA, these methods do not take into account the multidimensional structure of the data [12]. We could also cite other approaches based on combinations of various artificial intelligence techniques [13, 7]. However, several authors [14, 9] have compared most of these methods and shown that they do not necessarily detect the same subset of differentially expressed genes.

Nevertheless, the above-mentioned methods do help rank the genes for the development of biomarkers that can be used for class discovery. Differentially expressed genes are features used to discriminate subgroups of specimens. Many diseases are heterogeneous and characterized by the presence of several subgroups. This is the case of breast cancer [15]. The discovery of associations between prognostic

information and responses to therapy and the molecular signatures that characterize subgroups has greatly facilitated the development of treatments tailored to specific subgroups. To discover the subgroups concerned, we focus on the case where the experiments monitor the gene expression of different tissue samples, and the aim is to find a structure in this collection of unlabeled data to associate with a category, describing, for example, a subgroup of tumors. Several authors [16, 15, 5] have published such lists concerning breast cancer.

Once the subgroups are defined, it is possible to associate a new microarray with a class with class prediction by comparing a new specimen to features describing the subgroups. Several authors [17, 18, 16, 19] have proposed successful methods but it is still too difficult to use them to improve breast cancer prognosis or prediction [20]. The pitfalls have been emphasized by many authors [21, 1], these include the risk of over-fitting due to the high feature-to-sample ratio and the lack of validation due to the absence of independent datasets or the incorrect use of cross-validation techniques. Although the number of measured genes is in the thousands, it is assumed that only a few genes determine the type of a tissue. More recent studies focus on finding such groups of genes. In this paper, we do not try to find the minimum subsets of genes but look for gene sequences that we can use as features for the prediction of different classes.

### 3. Material and Methods

The class prediction system involves two steps: *Step 1- Building the classifier*: (1) The sequence preprocessing module transforms the raw data into gene sequences; (2) The feature selection module extracts sequential patterns, which have a close relationship with a given type of class; *Step 2-Evaluation of the classifier*: The classification module makes decisions concerning categories of testing samples and examines whether the classification results are confident or not.

Details of the methods used in each module are described in Sections 3.1, 3.2 and 3.3.

Microarray	G1	G2	G3	G4	G5
M1	6.76	6.65	6.65	9.65	6.75
Associated sequences	$\langle (G2G3G5)(G1)(G4) \rangle$ $\langle (G2G3)(G5G1)(G4) \rangle$				

Table 1: Gene expressions for microarray M1 and two associated data sequences with a minimal gap of 0.1

### 3.1. Sequence preprocessing module:

For each microarray, we have a list of genes associated with an expression value (see Table 1). The aim of this step is to build sequences by ordering the genes according to their value. In classical database vocabulary, the genes are called *items*. An *itemset*  $it_i$  is a non-ordered group of genes with similar expression. By considering the gaps between the expression of the genes (see Table 1),  $G2$  and  $G3$  are grouped in the same itemset because they have the same expression, but considering a minimal gap equal to 0.1,  $G5$  can be either grouped in  $it_1 = (G2G3G5)$  or in  $it_2 = (G1G5)$ . A *sequence*  $S = \langle it_a it_b \dots it_p \rangle$  is a non-empty and ordered list of  $p$  itemsets, i.e. groups of genes ordered according to their expression. From a microarray, we generate as many sequences as there are possible itemsets. Table 2 gives associated data sequences with a minimal gap of 0.1.

### 3.2. Feature selection module:

Table 2 gives an example of data used as input in the feature selection module. The aim of this step is to build sequential patterns [22], in our case frequent sequences of genes, to characterize a class. A pattern is supported by a microarray if the pattern is included in one or more sequences associated with a microarray. For example (see Table 2), the pattern  $P = \langle (G2)(G5) \rangle$  is included in one of the two  $M1$  data sequences. So,  $P$  is supported by the microarray  $class_1$ . The support of a pattern  $P$  in a class  $class_i$ , denoted by  $support_{class_i}(P)$ , is defined as the percentage of microarrays

Microarray	Class	Associated genes sequences.
M1	1	< (G2G3G5)(G1)(G4) > < (G2G3)(G5G1)(G4) >
M2	1	< (G1)(G4)(G2)(G3)(G5) >
M5	1	< (G2 G5)(G4)(G3)(G1) > < (G2)(G5G4)(G3)(G1) >
M3	2	< (G1)(G4)(G5)(G2)(G3) >
M4	2	< (G1)(G2)(G3)(G4)(G5) >

Table 2: **Gene sequences for 5 microarrays and 2 classes.** The microarrays M1, M2 and M5 are associated with the class 1 and M3 and M4 are associated with the class 2. According to a minimal gap, 2 sequences are associated with the microarray M1 and M5 and 1 sequence is associated with the microarrays M2, M3 and M4.

that support  $P$  in that  $class_i$ . For example,  $support_1(P) = 3/3$  and  $support_2(P) = 1/2$ . To obtain the most frequent patterns, a minimum support is provided and the patterns extracted must have a support greater this threshold, called the minimum support. For instance, if the minimum support is equal to  $2/3$ ,  $P$  is frequent in  $class_1$  but not in  $class_2$ . These definitions were given in a previous work [4], and an efficient algorithm was developed. In this paper, we have adapted the *PrefixSpan* algorithm [23] to take into account  $n$  sequences associated with a microarray. [24] have shown that Prefixspan is pseudo-polynomial. The complexity is  $O((2N) \wedge L)$  where  $N$  is the number of items and  $L$  is the maximum length of the initial gene sequences of the microarrays.

For class prediction, we only look for relevant patterns and not for all patterns. We rank the patterns to keep only the  $k$  best patterns for each class according to a measure based on the support value. For each pattern, the ranking measure is the difference between their two highest supports. For example (see Table 3), the gap between the two highest supports for pattern  $P1$  is 0.4 and for



Patterns	Supports in the different classes			Best Gap.
	Class 1	Class 2	Class 3	
P1	<b>0.4</b>	<b>0.8</b>	0.1	0.4
P2	0.1	<b>0.7</b>	<b>0.2</b>	0.5

Table 3: **Gaps obtained for two patterns for 3 classes.** For each pattern, support has been computed for each class. For a particular, the best gap is equal to the difference between the two highest supports. In this example P2 "is better" than P1 because P2 has the highest best gap.

P2, 0.5. Consequently, pattern P2 has a better rank than pattern P1. The interest of these patterns is that they can be used to distinguish classes but they also enable to take into account additional information with respect to differentially expressed genes, i.e. the order of expression of correlated gene groups.

### 3.3. Classification module:

The objective is to assign  $S = \langle (G1)(G2G3)(G4)(G5G6)(G7)(G8)(G9)(G10G11) \rangle$  an unlabelled sequence to a class (a category of tumor). We compare  $S$  to  $n\%$  of the ranking patterns by class. Consider the patterns  $P1, P2, P3$  (see Table 4), with  $P1, P3$  for *class2*, and  $P2$  for *class3*. When  $S$  contains a pattern, the score of  $S$  for the class associated with the pattern is increased by 1. Table 5 gives the score of  $S$  for each class. As the highest score is for *class2*,  $S$  is assigned to *class2*.

To evaluate the classification, we measure the *precision* and the *recall* for each class. Precision is the number of sequences correctly assigned to a class divided by the total number of sequences assigned to this class (correctly or not). The recall is the number of sequences correctly assigned to a class, divided by the number of sequences of real data belonging to this class. Table 6 gives an example of such a calculation. An *F-measure* combines Precision and Recall according to Formula 1:

Patterns	Class 1	Class 2	Class 3
$P1 = \langle (G1)(G2G3)(G4) \rangle$	0.2	<b>0.8</b>	0.1
$P2 = \langle (G5G6)(G7)(G8) \rangle$	0.1	0.0	<b>0.9</b>
$P3 = \langle (G9)(G10G11) \rangle$	0.3	<b>0.7</b>	0.1

Table 4: **Distribution of the sequential patterns in 3 classes.** As P1 and P3 have the highest support in Class 2, they are associated with Class 2. P2 is associated with Class 3.

Sequence	Class 1	Class 2	Class 3
$S = \langle (G1)(G2G3)(G4)(G5G6)(G7)(G8)(G9)(G10G11) \rangle$	0	2	1

Table 5: **Scores by class associated with sequence S.** According to the distribution in Table 4, the sequence S is included in 0 pattern of class 1, in 2 patterns of class 2 and in 1 pattern of class 3.

Class	Number of sequences		
	Associated with the class	Correctly labeled	Labelled
1	20	15	18

Table 6: **Example of results obtained after cross validation.** Precision=15/20, Recall=15/18 and F-measure= $2 \cdot (15/20 \cdot 15/18) / (15/20 + 15/18)$

$$F = 2 * \frac{precision * recall}{precision + recall} \quad (1)$$

## 4. Experiments

*Datasets and objectives:* We examined the following microarray datasets: a dataset provided by the IRCM which is not public, and datasets available online from Gene Expression Omnibus<sup>2</sup> KJX64-KJ125 (GSE2990), TAM (GSE6532), and TBG2 (GSE7390), focusing on a total of 624 human Affymetrix microarrays HG 133. All these microarrays share 22000 probesets<sup>3</sup>. To start the study, we focused on a subset of this list, the 128 genes identified by [5] for breast cancer. Below, we illustrate the power of classification based on sequential patterns in the case of breast cancer through one question: how to classify a new microarray according to its histological grade [25, 26]? This grade is a well-known variable with three values. It is used in clinical studies for its high prognostic potential in breast cancer. For example, patients with a grade 1 tumor have better survival rates than those with a grade 3 tumor. The distribution of the microarrays is 162 for grade 1, 274 for 2 and 185 for 3.




Figure 1: Extraction time vs. minimal support

<sup>2</sup><http://www.ncbi.nlm.nih.gov/geo/>

<sup>3</sup>Even though it is misusing the language, we use the term gene for probeset.

### *Extraction of sequential patterns:*

The extraction parameters are defined experimentally. As shown in Figure 1, in this type of data, it is difficult to extract patterns with a minimum support in a reasonable timeframe (we only keep patterns with a support greater than a given threshold named minimum support). We do not look for all patterns but only for a subset of patterns enabling efficient classification. For rapid extraction, we split the gene base into few groups and extract patterns from each. We experimentally vary the number of genes and the support. We observed that the most accurate approach is to form groups of 42 genes that can be extracted in 350 seconds with a minimum support of 0.4.




Figure 2: Stability of the generation of the patterns

In Figure 2, we gradually increase the number  $n$  of microarrays used for the extraction. For each  $n$ , we randomly select  $n$  microarrays per class, extract the patterns  $m$  times ( $m = 20$ ), and count the number of common patterns. The higher the  $n$ , the more extracted patterns are the same. Experimentally, we fixed  $n$  at 80 per grade to get a consistent training set and to keep enough microarrays to be able to validate the classifier in the validation set.

*Classification:* We used a cross-validation process to assess how the results of our classifier are generalized to an independent dataset. One round of cross-validation involves distributing the data

	Grade 1	Grade 2	Grade 3
Recall	.81	.15	.86
Precision	.39	.76	.54
F-Measure	.53	.25	.66
Involved genes	68	57	55
Total genes	104		

Table 7: **Evaluation of the classifier per grade.** For a total of 104 genes (68 involved in sequences associated with Class 1, 57 with Class 2 and 55 with Class 3), we obtain various measures of Recall, Precision and F-measure by class.

into complementary subsets, building the classifier on the training set, and validating the analysis on the validation set. According to the results deduced from Figure 2, we extracted sequential patterns on 80 specimens (38% of the total base) and validated the classifier on the remaining specimens (62%). To reduce variability, multiple rounds (50) were performed using different distributions. We used the 100 best sequential patterns for each grade.

Table 7 shows the evaluation of the method for the three grades. The method remains valid for more than three classes. We obtained optimistic results for grade 1 and 3 (Recall) and bad results for grade 2. These results are consistent with [5] who found that breast cancers of grades 1 and 3 had distinct gene expression profiles that appear in the patterns, but that grade 2 had heterogeneous gene expression profiles that are not captured by the patterns. In most cases, the specimens are wrongly classified in grade 1 or 3 (Precision). The line 4 of Table 7 corresponds to the genes used in the patterns that describe a grade. The last line gives the union between the genes involved in each grade. It should be noted that the genes are not the same for each grade. The genes can be ranked according to their efficiency for class prediction thank to the number of patterns in which they appear and all genes used to construct the pattern can be reduced considering the best genes.

Classifier	Grade 1 and 3									Grade 1, 2 and 3		
	IRCM			IRCM and online datasets			Online datasets			IRCM		
	R	P	F	R	P	F	R	P	F	R	P	F
Rules (9)	0.954	0.967	0.959	0.922	0.922	0.922	0.924	0.906	0.915	0.715	0.706	0.710
Bayes (8)	0.921	0.932	0.926	0.819	0.826	0.822	0.920	0.918	0.819	0.702	0.716	0.708
Functions (5)	0.955	0.970	0.962	0.902	0.901	0.902	0.917	0.918	0.917	0.760	0.802	0.779
Lazy (4)	0.909	0.939	0.923	0.922	0.931	0.926	0.937	0.943	<b>0.940</b>	0.727	0.721	0.724
Misc (3)	0.934	0.942	0.937	0.937	0.934	0.936	0.932	0.936	0.934	0.736	0.714	0.724
Tree (12)	0.928	0.944	0.936	0.943	0.944	<b>0.944</b>	0.938	0.943	<b>0.940</b>	0.765	0.770	0.767
SP	0.962	0.974	<b>0.968</b>	0.896	0.910	0.903	0.891	0.880	0.885	0.769	0.797	<b>0.782</b>

Table 8: **Classifier evaluation.** Family of classifiers available in Weka are compared to our method in the last line entitled SP in term of Recal, Precision and F-measure. We vary the number of class (Grade 1 and 3 / Grade 1, 2 and 3) and the datasets (IRCM, IRCM and online datasets and online datasets alone). The highest F-measure scores are in bold in this table.

By considering only grades 1 and 3, and the 3 grades (Table 8), we compared our classifier with those of Weka software that refer to the data mining community. We calculated the recall, the precision and the F-measure for each group of classifiers. Considering only grade 1 and 3 or only grade 3, we obtained the higher F-measure with the IRCM dataset in all cases. The results were least satisfactory when considering the combination of IRCM and online datasets or online datasets alone.

We can make two assumptions: 1) the online datasets are heterogeneous and it is more difficult to obtain relevant sequential patterns: the microarrays were obtained from patients undergoing different treatments, with different types of tumor and many others parameters that affect gene expression. 2) Our classifier is more effective for an imbalanced dataset. Unsatisfactory results were obtained for grade 2 tumors (table 7) with all the datasets, but optimistic results with the IRCM dataset. From a list of patterns, we can effectively classify tumors into grades. Unlike a list of differentially expressed genes specific to a class, the patterns can be used to compare different classes and thus provide answers to different questions concerning prognosis. We can take into account all the DNA microarrays available online and the associated contextual information to produce a bar code (list of

patterns) from a limited set of genes (one hundred). A category could be: a grade 2 tumor, between 2 and 3 cm, treated with hormones, etc. Once a patient is classified in a category, we can use the information about the future of the patient already assigned to a class to predict her resistance to the various therapies or to make a prognosis for each choice of therapy.

## 5. Conclusions and Prospects

In this paper, we focus on the classification of DNA microarrays based on sequential patterns. Our contribution is two-fold: (i) we have developed a classification technique based on sequential patterns and not on differentially expressed genes, which is the case of most of the methods cited in the literature; (ii) we checked it experimentally to verify the interest of these features for the classification of tumors according to their histological grade. We have shown that the method is effective at highlighting biological differences between grade 1 and 3 tumors and is better than other classifiers when the datasets are imbalanced. Like the other methods, the classification is not efficient for grade 2 tumors. We hope to improve these results by using another form of distribution described by [5]. We try now to improve the patterns extraction module to manage more genes. We can also go a step further and use this technique for prediction and prognosis.

## 6. Conflict of Interest

None declared.

## References

- [1] Simon RM, Dobbin K. Experimental design of DNA microarray experiments. *Biotechniques*. 2003;34:16-21.

- [2] Alon U, Barkai N et al. Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. *Natl Acad. Sci. USA.* 1999;96:6745-6750.
- [3] Rosenwald A, Wright G et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell Lymphoma. *N. Eng. J. Med.* 2002;346:1937-1947.
- [4] Dougherty ER. Small sample issues for microarray-based classification. *Comparative and Functional Genomics.* 2001;2:28-34.
- [5] Sotiriou C, Neo SY et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. *Proc. Natl. Acad. Sci.* 2003;100(18):10393-10398.
- [6] Van de Vijver MJ, He YD et al. A gene-expression signature as a predictor of survival in breast cancer. *N. Eng. J. Med.* 2002;347:1999-2009.
- [7] Paola S, Bringay S et al. Mining Discriminant Sequential Patterns for Aging Brain. *Int. Conf. AIME.* 2009;365-369.
- [8] Zupan B, Demsar J et al. Machine Learning for Survival Analysis: A Case Study on Recurrence of Prostate Cancer. *Int. Conf. AIMDM.* 1999;346-355.
- [9] Dudoit S, Yang YH et al. Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. *Stat. Sinica.* 2002;2:111-139.
- [10] Tusher VG, Tibshirani R et al. Significance analysis of microarrays applied to the ionizing radiation response. *Natl Acad Sci USA.* 2001;98:5116-21.
- [11] Baldi P, Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. *Bioinformatics.* 2001;17:509-19.



- [12] Nueda MJ, Conesa A et al. Discovering gene expression patterns in time course microarray experiments by ANOVA-SCA. *Bioinformatics*. 2007;23:1792-800.
- [13] Li L, Weinberg CR et al. Gene selection for sample classification based on gene expression data: study of sensitivity to choice of parameters of the GA/KNN method. *Bioinformatics*. 2001;17:1131-1142.
- [14] Choe SE, Boutros M et al. Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. *Genome Biol*. 2005;6:R16.
- [15] Sorlie C, Perou M et al. Gene expression patterns breast carcinomas distinguish tumor subclasses with clinical implications. *Natl. Acad. Sci. USA*. 2001;98(19).
- [16] Peng YH. A novel ensemble machine learning for robust microarray data classification. *Computers in Biology and Medicine*. 2006;36:553-573.
- [17] Alizadeh AA, Eisen MB et al. Distinct types of diffuse large b-cell lymphoma identified by gene expression profiling. *Nature*. 2000;403(6769):503-511.
- [18] Brown MP, Grundy WN et al. Knowledge-based analysis of microarray gene expression data by using support vector machines. *Natl Acad. Sci. USA*. 2000;97(1):262-267.
- [19] Wong TT, Hsu CH. Two-stage classification methods for microarray data. *Expert Systems with Applications*. 2008;34:375-383.
- [20] Pusztai L. Chips to bedside: incorporation of microarray data into clinical practice. *Clin Cancer Res*. 2006;12:7209-14.
- [21] Michiels S, Koscielny S et al. Prediction of cancer outcome with microarrays: a multiple random validation strategy. *Lancet*. 2005;365(9458):488-492.

- [22] Agrawal R, Srikant R. Fast algorithms for mining association rules. Int. Conf. on VLDB. 1994, 487-499.
- [23] Pei J, Han J et al. PrefixSpan: Mining Sequential Patterns Efficiently by Prefix-Projected Pattern Growth. Int. Conf. on Data Eng. 2001. 215-224.
- [24] Duong, G., Pei, J. Sequence data mining, Springer. August 2007.
- [25] Elston CW, Ellis IO. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathol.*1991;19:403-410.
- [26] Scarff RW, Torloni H. Histological typing of breast tumors. International histological classification of tumours. 1968;2(2):13-20.